SOX2 and colorectal carcinoma: Moreover, the elevated expression of SOX2 is significantly associated with the inferior disease-specific survival and progression-free interval of CRC patients (p = 0.004080, and p = 0.04581, respectively) (Figure 1B, and Figure 1C, respectively).